研究成果
年分
作者
期刊
研究名稱
2021
Liao JN, Chao TF, Hung CL*, Chen SA*.
Heart Rhythm. 2021; 18(4) : 538-544. (IF: 6.343)
The decrease in peak atrial longitudinal strain in patients with atrial fibrillation as a practical parameter for stroke risk stratification.
2021
Liao CT, Huang JL, Liang HW, Chung FP, Lee YH, Lin PL, Chiou WR, Lin WY, Hsu CY, Chang HY*.
ESC Heart Fail. 2021; 8(5): 4199-4210. (IF: 4.411)
The association between ivabradine and adverse cardiovascular events in acute decompensated HFrEF patients.
2021
Liang HW, Liao CT, Lin WY, Chung FP, Huang JL, Lee YH, Lin PL, Chiou WR, Hsu CY, Chang HY*.
J. Chin. Med. Assoc. 2021; 84(6) : 588-595. (IF: 2.743)
The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril/valsartan era: Medical expenses and clinical effectiveness.
2021
Li GY, Chen YY, Chien KL, Lin YJ, Kuo TT*, Chung FP*.
Front. Cardiovasc. Med. 2021;8:676897. (IF: 6.050)
Clinical Significance of Ventricular Tachyarrhythmias in Patients Undergoing Valve Replacement: A Nationwide Population-Based Study.
2021
Lee YH, Lin PL, Chiou WR, Huang JL, Lin WY, Liao CT, Chung FP, Liang HW, Hsu CY, Chang HY*
ESC Heart Fail. 2021; 8(2) : 1204-1215. (IF:4.411)
Combination of ivabradine and sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
2021
Lee TS*, Lu TM, Chen CH, Guo BC, Hsu CP*.
Redox Biol. 2021; 46:102108. (IF: 11.799)
Hyperuricemia induces endothelial dysfunction and accelerates atherosclerosis by disturbing the asymmetric dimethylarginine/ dimethylarginine dimethylaminotransferase 2 pathway.
2021
Kuo MJ, Chou RH, Lu YW, Guo JY, Tsai YL, Wu CH*, Huang PH*, Lin SJ.
J. Intensive Care. 2021; 9(1):40. (IF: 3.953)
Premorbid beta 1-selective (but not non-selective) beta-blocker exposure reduces intensive care unit mortality among septic patients.
2021
Lee HF, See LC, Li PR, Liu JR, Chao TF, Chang SH, Wu LS, Yeh YH, Kuo CT, Chan YH*, Lip GYH*
EUR. HEART J.-CARDIOVASC. PHARMACOTHER. 2021; 7(1) : 50-58. (IF: 6.617)
Non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation patients with concomitant peripheral artery disease.
2021
Lee HF, Chan YH, Li PR, Liu JR, Chao TF, Wu LS, Chang SH, Yeh YH, Kuo CT, See LC*, Lip GYH.
Can. J. Cardiol. 2021; 37(1) : 113-121. (IF: 5.352)
Oral Anticoagulants and Antiplatelet Agents in Patients With Atrial Fibrillation and Concomitant Critical Limb Ischemia: A Nationwide Cohort Study.
2021
Lee CY, Wu TC*, Lin SJ.
Clin. Ther. 2021; 43(1):195-210. (IF: 3.396)
Effects of Postoperative Percutaneous Coronary Intervention, Pharmacologic Treatment, and Predisposing Factors on Clinical Outcomes in Patients With and Without Type 2 Diabetes Along With Critical Limb Ischemia.